Anbogen Therapeutics partners with Tokyo University on ABT 301 research
Oncology company Anbogen Therapeutics signed a research agreement with the University of Tokyo on 24 August 2026 to test cancer drug ABT 301 across multiple tumor indications
Anbogen Therapeutics has entered into a Collaborative Research Agreement with The University of Tokyo to evaluate its selective Class I histone deacetylase inhibitor, ABT-301 (Imofinostat), across multiple solid tumor types using veterinary oncology models. Led by experts from the Laboratory of Veterinary Surgery, this collaboration aims to generate scientific evidence to support the expansion of ABT-301's human clinical indications and optimize its combination strategies.
The research team brings extensive expertise in translational oncology, cancer immunotherapy, and genomic medicine in companion animals, with a focus on naturally occurring cancers in dogs, which are widely recognized as clinically and molecularly analogous to their human counterparts.
Brief written by urgent.news from Vietnam Investment Review's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
